COVID-19 - VOGO participation in the development, production and distribution
of a rapid saliva-based screening test
VOGO (ISIN: FR0011532225 - Ticker: ALVGO) is announcing that it is
collaborating with scientists from the CNRS (French National Center for
Scientific Research) laboratory Sys2Diag, and with biotechnology company
SkillCell for providing a rapid saliva-based screening test, if the results of
the clinical trial are conclusive.
Faced with the current health crisis, it has been established that widespread
rapid testing of populations would have a decisive impact. The EasyCov test has
all the qualities to be able to meet this challenge.
Since April 11th, a clinical trial has been promoted by the Montpellier
University Hospital with SkillCell and scientists from the CNRS laboratory
Sys2Diag. If the results of the clinical trial are conclusive, an efficient and
reliable development, production and distribution chain for widespread rapid
testing of medical personnel could be ready as early as May.
All the details of the clinical trial project are developed in the press
release dated April 10, 2020 available on the CNRS website (1).
Development of a version of Easycov for the general public is in progress. As
an expert in developing audio and video communication systems for use where
there are large groups of people (sports venues for example) and operating
cutting-edge image, network and Artificial Intelligence (AI) technology, VOGO
has been selected to develop and launch the digital tool that will automate
results analysis via colorimetric reading of the EasyCov test, which would be
required for widespread screening of the population.
VOGO has already begun developing the technological tool (a smartphone app)
that will provide this automation.
In addition to this project, on which 25% of the company's R&D teams are
working, VOGO remains focused on its core Sportech, industry and services
Christophe Carniel, Co-Founder and Chief Executive Officer of VOGO, said:
"Our inclusion in this consortium is a clear recognition of our technological
expertise, our capacity for innovation and our teams' agility. We are equipped
to contribute to this strategic project while also staying the course in terms
of our R&D roadmap for our core business. Making this test widely available
would be a major step towards returning to normal life where sports and
cultural events with large crowds, which are impossible today, could resume.
This is a defining moment for our industry and our company."
VOGO develops, markets and distributes live & replay, audio and video solutions
for spectators and professionals in sports arenas. VOGO's disruptive solution
for spectators transforms the stadium experience by providing multi- camera
content on demand for viewing on tablets and smartphones, irrespective of the
number of people connected. In the professional sphere, VOGO's video solution
provides analytical and decision-making tools (referee assistance, medical
diagnostics, coaching, etc.). The acquisition of Vokkero(r) in October 2019
enriched this range of professional solutions, with the integration of an
internationally recognised line of audio communications systems. All of the
Group's technologies have patent protection. They have already been implemented
across more than 20 different sport disciplines. VOGO is present in France
(Montpellier and Crolles) and in North America, with an office in New York. The
Group has been listed on the Euronext Growth Paris stock market since November
2018 (ISIN code: FR0011532225 - ALVGO).